CAR-T in R/R MM: Patient Selection & Treatment Sequencing

January 10, 2025

By Saad Z. Usmani, MD, MBA, FACP
Carlyn Rose Tan, MD

Opinion

Video

Panelists discuss how institutional decisions to implement early-line chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma are influenced by patient characteristics, logistical capabilities, cost considerations, and subsequent treatment strategies.

EP: 1.Highlighted Data Review of CAR-T in Early R/R MM

EP: 2.Expert Insights: Distinguishing between CARTITUDE-4 vs. KarMMa-3 Trials

Now Viewing

EP: 3.CAR-T in R/R MM: Patient Selection & Treatment Sequencing

EP: 4.CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel

EP: 5.MSKCC Insights: CAR T Referral Process

EP: 6.Overview of the CAR T-Cell Therapy Process: Apheresis, Manufacturing, Potential Bridging Therapies, Lymphodepletion, and Infusion

EP: 7.Collaboration With Community Colleagues: Comanagement and Transitions of Care

EP: 8.CAR T Referral Process: Challenges Seen and How They Can Be Addressed

EP: 9.MSKCC Experiences: Successful CAR T Collaborations With Community and International Providers

EP: 10.CAR-T Clinical Trials: Potentially Moving CAR T Into Earlier Lines of MM Treatment

EP: 11.Applying Evidence to Clinical Practice: 63-Year-Old Patient With R/R MM Post Dara-VRd Induction Scenario

EP: 12.CAR T in R/R MM: Key Takeaways and Pearls

Video content above is prompted by the following:

What key factors influence your institution’s decision to utilize chimeric antigen receptor T-cell (CAR T) therapy in earlier lines of treatment for relapsed/refractory multiple myeloma?
If you choose to utilize CAR T in earlier lines of therapy, what might you do next and why?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!